December 1, 2022

Wenxin (Vincent) Xu, MD, provides insight on biomarkers in renal cell carcinoma.

Refining current regimens and other emerging approaches will be delineated in melanoma, according to Omid Hamid, MD.

Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.

In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.

Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Primary brain cancers are aggressive, resulting in low survival rates, and pose significant challenges to effective treatment, but ongoing studies signal hope for patients with there tumors.

Results of a study conducted by the Community Oncology Alliance showed significant reductions in screenings at the beginning of the COVID-19 pandemic.

According to John M. Burke, MD, significant attention has been paid in recent years to the problem of physician burnout and as oncologists continue to care for patients, it important to also care for themselves.